首页 > 市场调查报告书 > 製药

生物标记

市场调查报告书

商品编码

1475224

全球 PARP 抑制剂生物标记市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global PARP Inhibitor Biomarkers Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 238 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球 PARP 抑制剂生物标记市场需求预计将从 2023 年的 9,1123 万美元达到 2,0,2032 万美元的市场规模，2024 年至 2032 年研究期间复合年增长率为 9.25%。

PARP 抑制剂生物标记是识别可能对聚（ADP-核糖）聚合酶（PARP）抑制剂治疗产生积极反应的癌症患者的分子标记。这些生物标记包括 DNA 修復途径的基因突变或改变，例如 BRCA1 和 BRCA2 基因，以及与同源重组缺陷 (HRD) 或合成致死相关的其他基因。透过基因检测或肿瘤组织的分子谱分析这些生物标记物，肿瘤学家可以确定PARP 抑制剂治疗对个别患者的适用性，并定制治疗策略，以最大限度地提高卵巢癌、乳腺癌和前列腺癌的疗效并最大限度地减少副作用。

市场动态

人们对癌症生物学和 DNA 损伤修復途径在癌症进展中的作用的深入了解，推动了 PARP 抑制剂作为一类有前途的抗癌药物的发展。随着PARP 抑制剂在治疗具有特定基因突变（如BRCA1 和BRCA2）的癌症方面显示出疗效，人们越来越需要能够准确预测患者对PARP 抑制剂治疗的反应并识别最有可能从治疗中受益的个体的生物标记。此外，伴随诊断和基因组分析技术的出现使得能够识别与 PARP 抑制剂敏感性或抗药性相关的生物标记物，从而促进患者分层和治疗决策。此外，肿瘤学中越来越多地采用精准医学方法，推动了对针对特定分子途径和肿瘤特征的生物标誌物驱动疗法的需求，从而最大限度地减少与治疗相关的毒性并最大限度地提高治疗效果。

此外，生物标记发现技术的进步，包括次世代定序 (NGS)、基因表现谱和液体活检测定，能够识别 PARP 抑制剂反应的新型预测生物标记物，从而扩大适合治疗的潜在患者群体。随着製药公司投资开发 PARP 抑制剂和伴随诊断，对生物标记验证研究和监管部门批准用于 PARP 抑制剂治疗的生物标记驱动的伴随诊断的需求日益增长。此外，癌症发生率的上升和对个人化治疗选择的需求不断增加推动了 PARP 抑制剂生物标记的市场。然而，随着癌症诊断和治疗领域的不断发展，癌症研究的进步、新的治疗方式和不断变化的监管要求可能会在未来几年挑战 PARP 抑制剂生物标记市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球 parp 抑制剂生物标记市场的各个细分市场进行了包容性评估。 parp 抑制剂生物标记产业的成长和趋势为本研究提供了整体方法。

市场区隔

parp 抑制剂生物标记市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按产品分类

套件
化验

按服务分类

BRCA 1 和 2 测试
人力资源开发测试
HRR测试
其他的

按申请

乳癌
卵巢癌
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲 PARP 抑制剂生物标记物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。 PARP抑制剂生物标记市场的主要参与者包括Myriad Genetics, Inc.、AmbryGenetics、Thermo Fisher Scientific Inc.、Illumina, Inc.、Centogene NV、厦门诊断有限公司、Invitae Corporation、NeoGenomics Laboratories.、Qiagen、Agilent Technologies , Inc. 本部分包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概览、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：PARP 抑制剂生物标记公司的竞争格局

PARP抑制剂生物标记市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
Myriad Genetics Inc.

公司简介
公司收入
产品
最近的发展

AmbryGenetics

公司简介
公司收入
产品
最近的发展

Thermo Fisher Scientific Inc.

公司简介
公司收入
产品
最近的发展

Illumina Inc.

公司简介
公司收入
产品
最近的发展

Centogene NV

公司简介
公司收入
产品
最近的发展

Amoy Diagnostics Co. Ltd.

公司简介
公司收入
产品
最近的发展

Invitae Corporation

公司简介
公司收入
产品
最近的发展

NeoGenomics Laboratories.

公司简介
公司收入
产品
最近的发展

Qiagen

公司简介
公司收入
产品
最近的发展

Agilent Technologies Inc.

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114327

The global demand for PARP Inhibitor Biomarkers Market is presumed to reach the market size of nearly USD 2020.32 Million by 2032 from USD 911.23 Million in 2023 with a CAGR of 9.25% under the study period 2024 - 2032.

PARP inhibitor biomarkers are molecular markers that identify cancer patients likely to respond positively to treatment with poly (ADP-ribose) polymerase (PARP) inhibitors. These biomarkers include genetic mutations or alterations in DNA repair pathways, such as BRCA1 and BRCA2 genes, and other genes associated with homologous recombination deficiency (HRD) or synthetic lethality. By analyzing these biomarkers through genetic testing or molecular profiling of tumor tissues, oncologists can determine the suitability of PARP inhibitor therapy for individual patients and tailor treatment strategies to maximize efficacy and minimize side effects in ovarian, breast, and prostate cancer.

MARKET DYNAMICS

The spurring understanding of cancer biology and the role of DNA damage repair pathways in cancer progression drive the growth of PARP inhibitors as a promising class of anticancer agents. With PARP inhibitors showing efficacy in treating cancers with specific genetic mutations such as BRCA1 and BRCA2, there is a growing need for biomarkers that can accurately predict patient response to PARP inhibitor therapy and identify individuals most likely to benefit from treatment. Additionally, the emergence of companion diagnostics and genomic profiling technologies enables the identification of biomarkers associated with PARP inhibitor sensitivity or resistance, facilitating patient stratification and treatment decision-making. Moreover, the increasing adoption of precision medicine approaches in oncology drives the demand for biomarker-driven therapies that target specific molecular pathways and tumor characteristics, minimizing treatment-related toxicity and maximizing therapeutic efficacy.

Furthermore, advancements in biomarker discovery technologies, including next-generation sequencing (NGS), gene expression profiling, and liquid biopsy assays, enable the identification of novel predictive biomarkers for PARP inhibitor response, expanding the potential patient population eligible for treatment. With pharmaceutical companies investing in developing PARP inhibitors and companion diagnostics, there is a growing need for biomarker validation studies and regulatory approval of biomarker-driven companion diagnostics for PARP inhibitor therapy. Additionally, the rising incidence of cancer and the increasing demand for personalized treatment options drive the market for PARP inhibitor biomarkers. However, advancements in cancer research, new treatment modalities, and evolving regulatory requirements may challenge the PARP Inhibitor Biomarkers market growth in the coming years as the landscape of cancer diagnostics and therapeutics continues to grow.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of parp inhibitor biomarkers. The growth and trends of parp inhibitor biomarkers industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the parp inhibitor biomarkers market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Kits
Assays

By Services

BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others

By Application

Breast Cancer
Ovarian Cancer
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the PARP Inhibitor Biomarkers market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the PARP Inhibitor Biomarkers market include Myriad Genetics, Inc., AmbryGenetics, Thermo Fisher Scientific Inc., Illumina, Inc., Centogene N.V., Amoy Diagnostics Co., Ltd., Invitae Corporation, NeoGenomics Laboratories., Qiagen, Agilent Technologies, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.'

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PARP INHIBITOR BIOMARKERS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Services
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data
5.3. Analysis By Product
5.4. Kits Historic and Forecast Sales By Regions
5.5. Assays Historic and Forecast Sales By Regions

6. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY SERVICES

6.1. Overview By Services
6.2. Historical and Forecast Data
6.3. Analysis By Services
6.4. BRCA 1 & 2 Testing Historic and Forecast Sales By Regions
6.5. HRD Testing Historic and Forecast Sales By Regions
6.6. HRR Testing Historic and Forecast Sales By Regions
6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data
7.3. Analysis By Application
7.4. Breast Cancer Historic and Forecast Sales By Regions
7.5. Ovarian Cancer Historic and Forecast Sales By Regions
7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PARP INHIBITOR BIOMARKERS COMPANIES

9.1. PARP Inhibitor Biomarkers Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PARP INHIBITOR BIOMARKERS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Myriad Genetics Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. AmbryGenetics
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Thermo Fisher Scientific Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Illumina Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Centogene N.V.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Amoy Diagnostics Co. Ltd.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Invitae Corporation
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. NeoGenomics Laboratories.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Qiagen
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Agilent Technologies Inc.
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments